Standard BioTools Inc. (LAB)

Standard BioTools reported a Q1 2025 loss, topping revenue estimates, and Q2 2025 earnings of -$0.05, which was better than the analyst estimate of -$0.07. On June 22, 2025, Standard BioTools entered into an agreement with Illumina to sell its SomaScan business for up to $425 million in cash. In September 2025, Standard BioTools announced a restructuring plan that included a reduction of approximately 15% of its global workforce. In August 2025, TD Cowen downgraded Standard BioTools to Hold from Buy. The stock price has experienced fluctuations, with a rise above its 50-day and 200-day moving averages in early October 2025. Over the last six months, the stock has seen a 12.70% rise, though it has decreased by -21.98% over the last year. Short interest in Standard BioTools increased by 0.50% recently.

Demand seasonality for Standard BioTools' products and services is influenced by customer procurement cycles, which can lead to variability in revenue. The company's diverse customer base suggests that various budget cycles and research funding timelines could contribute to this seasonality.

Standard BioTools, Inc. is a life sciences tools company focused on developing, manufacturing, and selling instruments, consumables, and services for biomedical researchers. The company's offerings generate data across early discovery, translational, and clinical research, with a focus on areas such as oncology, immunology, and immunotherapy. Its operations are divided into two primary segments: Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services for protein identification, utilizing proprietary SomaScan, mass cytometry (CyTOF®), and microfluidics technologies. The Genomics segment includes instruments, consumables, software, and services for identifying genes (DNA, RNA) and their functions, including the Biomark X9™ System for High-Throughput Genomics.

Standard BioTools is headquartered in South San Francisco, California, and has a facility in Markham, Ontario, Canada. It serves academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, with sales offices and distributors in Europe, Australia, and Asia-Pacific. A majority of its revenue is derived from the Americas.

Standard BioTools' brand reputation has been influenced by product launches and collaborations, enhancing its reputation as an innovator. The workforce reduction plan and a downgrade by TD Cowen could negatively impact employee morale and investor confidence. The sale of the SomaLogic business could also lead to questions about the company's long-term direction.

Institutional investors hold a significant majority stake in Standard BioTools, owning approximately 52% to 73.82% of the company's shares. Major institutional owners include Casdin Capital, LLC, Viking Global Investors Lp, BlackRock, Inc., Vanguard Group Inc, Long Focus Capital Management, Llc, Geode Capital Management, Llc, State Street Corp and Morgan Stanley. Eli Casdin is identified as the largest individual insider shareholder, owning 109.58 million shares, representing 28.69% of the company. Hedge funds collectively own about 16% of Standard BioTools.